Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Takeda Pharmaceutical Co ( (JP:4502) ) has provided an announcement.
Takeda Pharmaceutical Company reported its consolidated financial results for the three-month period ending June 30, 2025. The company experienced a decline in revenue by 8.4% compared to the previous year, but saw an increase in operating profit and net profit by 11.0% and 30.4% respectively. The company maintains its management guidance for the fiscal year ending March 31, 2026, with expectations of broadly flat growth in core revenue, core operating profit, and core EPS.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan, with stock exchange listings in Tokyo, Nagoya, Sapporo, and Fukuoka. The company is led by President & CEO Christophe Weber and focuses on developing and providing pharmaceutical products.
Average Trading Volume: 3,933,486
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen6823.2B
See more insights into 4502 stock on TipRanks’ Stock Analysis page.